Articles related to BREAST CANCER

Disease recurrence in HR+/HER2– early BC (EBC) can occur over decades; however, the hazard of recurrence is highest during the first 2 years of adjuvant endocrine therapy, a period associated with endocrine resistance and early metastatic progression.

The primary end point was the area under the curve (AUC) of the daily worst bone pain score (assessed using the “worst pain” question from the Brief Pain Inventory, a 0 to 10 numerical rating scale [NRS]) for 5 consecutive days in the first chemotherapy cycle.

“Given that studies project cases will increase by 38-54% and deaths by 68-71% by 2050, prevention through lifestyle modification becomes critically important.” – Amy Bremner, MD

For clinicians and patients alike, the message from this large registry-based analysis is clear: early pregnancy loss, whether induced or spontaneous, does not confer an elevated risk of subsequent breast cancer.

“As an oncologist, when patients lost their hair, my response was, ‘Don’t worry. It will grow back.’ And it will grow back. But it really sucks as you’re waiting.” – Dr. Sue Hwang

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.